Literature DB >> 17448296

Collagen degradation products and proinflammatory cytokines in systemic and localized scleroderma.

R Becvár1, H Hulejová, M Braun, J Stork.   

Abstract

The aim of this study was to assess the degradation of collagen type I and proinflammatory cytokines in systemic and localized scleroderma compared with psoriasis and healthy controls. Total 99 individuals were examined - 24 with SSc, 22 with LSc, 39 patients with PsV and 14 healthy controls. U-PD and U-DPD were measured using a sensitive isocratic HPLC method. Serum levels of IL-6 and soluble IL-2R were assayed using commercial ELISA kits. In the SSc group U-PD and U-DPD levels (nmol/mmol creatinine) were increased compared with controls (P = 0.001) and with PsV (P = 0.006). IL-6 levels were increased compared with controls (P = 0.004) and with PsV (P = 0.002). IL-2R concentrations were insignificantly increased in comparison with controls and were lower than in PsV, but the difference was not significant. In the LSc group excretion of U-PD and U-DPD did not differ from controls, but was insignificantly decreased compared with PsV. IL-6 levels were increased compared with controls (P = 0.001) and also with PsV (P = 0.03). IL-2R concentrations were significantly increased in comparison with controls only (P = 0.03). In patients with SSc our data have shown the most intensive collagen degradation and simultaneously an active inflammation, as documented by IL-6, which reflects the pathological processes in the skin and visceral organs compared with PsV patients and healthy individuals. In the LSc group collagen degradation was similar to that in control groups, but a certain inflammatory activity was observed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17448296

Source DB:  PubMed          Journal:  Folia Biol (Praha)        ISSN: 0015-5500            Impact factor:   0.906


  6 in total

Review 1.  Biomarkers in systemic sclerosis.

Authors:  Susan V Castro; Sergio A Jimenez
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

2.  Assessment of tissue fibrosis in skin biopsies from patients with systemic sclerosis employing confocal laser scanning microscopy: an objective outcome measure for clinical trials?

Authors:  Joanna Busquets; Francesco Del Galdo; Eugene Y Kissin; Sergio A Jimenez
Journal:  Rheumatology (Oxford)       Date:  2010-03-04       Impact factor: 7.580

3.  [Expression of pituitary tumor-transforming gene-1 and its pathogenic role in systemic sclerosis].

Authors:  Anqiao Yang; Yan Huang; Yuting Zhang; Kai Yang; Jiucun Wang; Qingmei Liu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2020-11-30

4.  Skin autofluorescence, as marker of accumulation of advanced glycation endproducts and of cumulative metabolic stress, is not increased in patients with systemic sclerosis.

Authors:  M E Hettema; H Bootsma; R Graaff; R de Vries; C G M Kallenberg; A J Smit
Journal:  Int J Rheumatol       Date:  2011-09-29

5.  Apoptosis modulation as a promising target for treatment of systemic sclerosis.

Authors:  Stéphane Chabaud; Véronique J Moulin
Journal:  Int J Rheumatol       Date:  2011-09-06

6.  Supernatants from culture of type I collagen-stimulated PBMC from patients with cutaneous systemic sclerosis versus localized scleroderma demonstrate suppression of MMP-1 by fibroblasts.

Authors:  Monica Brown; Arnold E Postlethwaite; Linda K Myers; Karen A Hasty
Journal:  Clin Rheumatol       Date:  2012-02-25       Impact factor: 2.980

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.